Noninferiority trials have dramatically increased in number as researchers try to prove new medical devices and drugs are as safe and effective as established therapies. However, the way these studies are designed and interpreted could use a revamp, a pair of reviewers wrote in The New England Journal of Medicine.

Why are people so willing to act following a disaster—whether natural or human-inflicted—but less receptive to requests from blood centers?

There’s an elephant in the room regarding America’s healthcare spending, said Dariush Mozaffarian, a cardiologist and public health scientist from Tufts University. And that elephant is in the shape of cheeseburgers, piles of sodium and bottles of sugary drinks.

A team of researchers who analyzed rates of do-not-resuscitate (DNR) orders in California are suggesting DNR mortality numbers should be taken into account when calculating hospital risk-adjusted heart failure mortality metrics.

Medicare paid at least $1.5 billion over a decade to replace seven types of faulty heart devices, according to a HHS Office of Inspector General report released Oct. 2.

In its first-ever scientific statement on the subject, the American Heart Association said meditation could be a useful treatment tool for cardiac patients, but the organization was careful not to recommend the practice over traditional medical recommendations.

Just over 30 percent of patients who receive a pricey prescription for the cholesterol-lowering medications known as PCSK9 inhibitors (PCSK9i) are able to pay for the drugs, new research states.

A study of antibiotic delivery methods in France revealed an important finding that could be applied to other pharmaceuticals around the world: patients receiving a per-unit dispensing of pills demonstrated greater adherence to the medication than those receiving prepackaged boxes.